Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin
about
M2e-Based Universal Influenza A VaccinesTowards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensingImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsUniversal influenza virus vaccines and therapeutic antibodies.Development of universal influenza vaccines based on influenza virus M and NP genes.Universal influenza vaccines, a dream to be realized soon.Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.The personal touch: strategies toward personalized vaccines and predicting immune responses to them.Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliThe adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.Systems biology of vaccination for seasonal influenza in humans.Reevaluating the hype: four bacterial metabolites under scrutiny.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligandTrial Watch: Experimental Toll-like receptor agonists for cancer therapyAn Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In VivoProtective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.Development of a universal CTL-based vaccine for influenza.Adjuvant immunotherapies as a novel approach to bacterial infections.Adjuvants in micro- to nanoscale: current state and future direction.A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection.6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine.Universal influenza vaccine: the holy grail?Flagellin-PAc fusion protein is a high-efficacy anti-caries mucosal vaccine.DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.
P2860
Q26783493-D0F8D4D5-9511-49CA-8FC4-CF40E42FFC81Q27003874-A89D3083-8E67-47EB-AF99-1CAA3BEDEA17Q28972540-44C61737-351D-4312-A3FA-9BA4211754B6Q30151337-A2B91259-93EF-49F1-83D6-D38BF0F22C4AQ30355116-07468087-CDC9-44F7-8D8D-C385D62FBE54Q30361950-ED3FA03C-4411-4C84-86E7-B94F201AA10FQ30376724-840EEA00-B1B8-4D61-8401-6F96BD350B3BQ33813977-0891BC29-DE65-4C79-8D74-CF68DD258EB6Q34105207-63AC503D-D6D2-4A40-B382-97EE73B1806DQ34533990-0A9F6F3C-6036-42D9-9B37-4D7BE3F74330Q34778787-A198394D-11B0-4E97-8363-977F0FA216E1Q35118722-09F135B7-E17E-4C3F-B8C3-0DACEA1A50EAQ35426826-1750F7AC-669D-4FB4-A4A2-DC10704CE651Q35656657-784F57EB-7131-494C-8516-3CC28476811AQ35758568-E4F3CDC2-4B55-44B3-A937-76E50A2CA846Q35772241-6F79D18E-75CF-4D6D-A8B2-A16C402BF5DFQ35886473-924DA929-9EB4-4046-B868-9F5B844C5485Q36154739-AB9A3F86-4086-482D-ADD0-857CB3145722Q36194849-6134C720-68E4-4A75-9D05-955E89503B81Q36675921-C0DEAA42-F57E-4C1F-BEF3-954AED20EA1AQ37336064-127EA3F4-C9AE-4059-8C80-CFA0D8B1656DQ38075677-97F41893-1382-41C4-BED4-E606E8E291E6Q38096056-072EC37A-55AC-4FDE-B354-2604DD6F76A0Q38520210-9C095869-EDA6-4E51-931B-E81356D0090BQ38667809-010F8BCE-1D6E-44F1-ACFF-A7E2C20D6A43Q38678908-440211A7-60AD-499E-BAFF-4A8D6774D9B7Q40911284-0C49C861-2AD4-4C62-B690-BB83D5B041A4Q43692141-3726E84B-65D6-4F58-9212-5A032B3B2008Q43954962-EE9DE6C3-7600-4DED-B960-5FE356F55D35Q52729536-3DCE855F-2CF3-4439-8BFD-B55BAF7FDD1E
P2860
Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@ast
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@en
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@nl
type
label
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@ast
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@en
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@nl
prefLabel
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@ast
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@en
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@nl
P2093
P2860
P1433
P1476
Immunopotentiation of trivalen ...... d to the TLR5 ligand flagellin
@en
P2093
Alan R Shaw
Anita Shanker
Casey Johnson
David N Taylor
H Keipp Talbot
Lynda Tussey
Michael T Rock
Uma Kavita
P2860
P304
P356
10.1371/JOURNAL.PONE.0014442
P407
P577
2010-12-28T00:00:00Z